Fulcrum Therapeutics promotes Mel Hayes to COO with salary increase and stock option grant

Fulcrum Therapeutics, Inc.

Mel Hayes promoted from chief commercial officer to chief operating officer effective August 9, 2022.
Annual base salary increased to $453,000 retroactive to July 1, 2022.
Granted option to purchase 137,000 shares at $7.40 per share, vesting over four years.
Hayes previously served as CCO since September 2021; prior roles include Sanofi-Genzyme and Bioverativ.
Employment agreement setting terms for severance and change-in-control benefits filed as Exhibit 10.1.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Mel Hayes

Chief Operating Officer

FULC · Fulcrum Therapeutics, Inc.

Effective: 2022-08-09
Filed: August 11, 2022, 7:59 PM ET

On August 11, 2022, Fulcrum Therapeutics, Inc., or Fulcrum, announced that its board of directors promoted Mel Hayes, its current chief commercial officer, to the position of chief operating officer effective August 9, 2022, such date the Effective Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mel Hayes changed role as Chief Operating Officer at Fulcrum Therapeutics, Inc..

Action: promoted
Role: Chief Operating Officer

Exact text from the filing

On August 11, 2022, Fulcrum Therapeutics, Inc., or Fulcrum, announced that its board of directors promoted Mel Hayes, its current chief commercial officer, to the position of chief operating officer effective August 9, 2022, such date the Effective Date.

View on SEC.gov

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-217954

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.